Why Is Somatropin So Hard to Find? [Explained for 2026]

If you or a family member takes somatropin — the recombinant human growth hormone sold under brand names like Norditropin, Genotropin, and Omnitrope — you've likely experienced the frustration of calling multiple pharmacies only to be told it's out of stock. You're not imagining things. Somatropin has been in an active nationwide shortage since late 2022, and the situation has grown more complicated as multiple brands have been discontinued entirely.

Here's a clear, up-to-date explanation of why somatropin is so difficult to find in 2026 — and what you can do about it.

What Is Somatropin and Who Needs It?

Somatropin is a synthetic form of human growth hormone (HGH), made through recombinant DNA technology. It is chemically identical to the growth hormone naturally produced by the pituitary gland. Doctors prescribe it for children who aren't growing normally due to growth hormone deficiency (GHD), Turner syndrome, Prader-Willi syndrome, Noonan syndrome, or other conditions. Adults with GHD also use it, as do people living with HIV-related wasting.

Somatropin is not a drug that can be taken orally or swapped out easily. It requires subcutaneous injections, specialty pharmacy dispensing, cold-chain storage, and careful physician oversight. That's part of what makes navigating a shortage especially difficult for patients and families.

When Did the Somatropin Shortage Begin?

The American Society of Health-System Pharmacists (ASHP) created a drug shortage bulletin for somatropin injection in November 2022. Since then, the shortage has been ongoing, periodically updated, and involving multiple manufacturers. In December 2024, ASHP confirmed that Genentech had discontinued Nutropin AQ NuSpin presentations, and Eli Lilly had discontinued Humatrope entirely — two major players in the somatropin market.

Novo Nordisk's Norditropin has remained the most consistently available brand, though even it has faced disruptions. The 30 mg/3 mL Norditropin FlexPro pen was discontinued in late 2025. Meanwhile, Pfizer's Genotropin had intermittent supply constraints through at least April 2025.

Why Is Somatropin in Shortage?

Several factors have combined to make the somatropin shortage persistent and hard to resolve:

Unprecedented demand growth. Pfizer noted in December 2024 that demand has been "high and unpredictable" — it scaled Genotropin production to 3.5 times normal levels in 2023 compared to 2022, and still couldn't keep up.

Manufacturing complexity. Recombinant growth hormone is a biologic drug made through a complex fermentation and purification process. Any disruption at a contract manufacturing facility — as happened with Eli Lilly's Humatrope — can cause months of delays.

Market consolidation. With Humatrope and Nutropin AQ NuSpin discontinued, fewer brands remain available. Each discontinuation pushes more patients to compete for supply from the remaining manufacturers.

Cold-chain and specialty requirements. Somatropin must be refrigerated and dispensed through specialty pharmacies. Not every pharmacy stocks every brand, and many only carry one or two products.

Which Brands Are Affected in 2026?

The shortage landscape has shifted significantly since 2022. Here's the current status as of 2026:

Norditropin (Novo Nordisk): Most consistently available brand. The 5 mg/1.5 mL, 10 mg/1.5 mL, and 15 mg/1.5 mL FlexPro pens are generally available, though regional shortages occur. The 30 mg/3 mL size was discontinued in late 2025.

Genotropin (Pfizer): Available but has experienced intermittent supply constraints. Pfizer has significantly scaled up production and remains committed to the product.

Omnitrope (Sandoz/Novartis): Generally available, though individual pharmacy stock varies.

Humatrope (Eli Lilly): Discontinued. No longer commercially available.

Nutropin AQ NuSpin (Genentech): Discontinued in December 2024.

Saizen, Zomacton: Availability varies; limited specialty pharmacy distribution.

38,004+ patients found their medications in stock

38K+

Find Somatropin In Stock Today →

Is the Somatropin Shortage Getting Better?

Partially — but the market has fundamentally changed. With fewer brands available, patients must work harder to locate supply. The remaining manufacturers (primarily Novo Nordisk and Pfizer) have increased production, but ongoing high demand means availability is still inconsistent depending on location, dose, and brand.

Once-weekly alternatives — somapacitan (Sogroya), lonapegsomatropin (Skytrofa), and somatrogon (Ngenla) — have become more prominent as substitutes and may ease demand on daily somatropin products over time.

What Should Patients Do Right Now?

If you're having trouble filling your somatropin prescription, here are the most effective steps:

Contact your prescriber. Ask whether switching brands (e.g., from Humatrope to Norditropin) is clinically appropriate. Your doctor can also check if a once-weekly product would work for your situation.

Call multiple specialty pharmacies. Stock varies widely from pharmacy to pharmacy. What one pharmacy doesn't have, another might.

Use medfinder.

Rather than spending hours calling pharmacies yourself, medfinder calls pharmacies near you to find which ones currently have your somatropin in stock. You provide your medication, dose, and location — medfinder does the calling and texts you the results.

Ask about alternatives. If your exact brand isn't available, your doctor may be able to prescribe a once-weekly GH product or a different somatropin brand that is in stock.

Skip the calls, skip the stress.

Find Somatropin In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

The Bottom Line

The somatropin shortage is real, ongoing, and has been worsened by manufacturer discontinuations. But somatropin is still available — it just requires more effort and flexibility to find. Read our full 2026 shortage update and our guide on how to find somatropin in stock near you for more detailed steps.